MELBOURNE, Australia, May 17, 2023 Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced. | May 17, 2023
MELBOURNE, Australia, May 08, 2023 Opthea Limited , a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced. | May 8, 2023
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today